Your donations at work. Attached are several publications detailing research partially funded by FMCT. The paper titled: Press Pulse: A novel therapeutic strategy for the metabolic management of cancer,highlights a theoretical, guiding strategy to use synergistic, combinations of metabolic acting therapies to help treat cancer.
Dr. Seyfried, other than Otto Warburg himself, may well be considered the godfather of the metabolic theory of cancer.
In March 2012, Nobel Prize winner James Watson gave a seminar at Yale University entitled “Driven by Ideas”.
Glioblastoma Multiforme (GBM) is the most aggressive form of brain cancer. Median time of survival is about 15 months from diagnosis. Standard therapy for GBM includes surgical resection followed by
A newly released article titled “News from the Front in War on Cancer – Mission Not Accomplished” from Scientific American highlights the flawed paradigm
In December of 2004, our 4 year old son Raffi was diagnosed with a brain tumor. After three surgeries and several failed drug protocols, it was clear that the tumor was winning. Raffi's vision, language and motor skills deteriorated and a cascade of endocrine problems affected many vital functions.
Prevention is always the best and easiest way to avoid disease. We are all aware of the lifestyle adjustments necessary to prevent heart disease and diabetes, but beyond smoking, the necessary lifestyle adjustments to prevent cancer are not always clear.
Not all scientists are created equal. We are reminded of this right now as the Nobel Prize Committee is awarding Nobel Prizes to those few who push the boundaries of science -- that ephemeral edge, dividing the know from the unknown. It is worth while to remember that many of those receiving that most coveted prize, have had to face various degrees of skepticism and derision throughout their careers -- until their ideas are ultimately proven correct in the end.
Hello, this is Travis Christofferson the founder of SCSC. For the last year I have "gone dark" while I wrote a book about the metabolic theory of cancer.
In May of 2016 we awarded a substantial grant to Dr. Thomas Seyfried's lab at Boston College. The grant is funding the exploration of a cocktail of metabolic therapies in a metastatic mouse model. The experiment will test the combination of the ketogenic diet, glycolytic inhibitors, oxygen therapy, glutamine inhibitors, exogenous ketones, and other metabolic targeting therapies in combination.
We have decided to change the name of our foundation from The Single Cause Single Cure Foundation, to The Foundation for Metabolic Cancer Therapies. We think this name better reflects our ethos. It was pointed out that perhaps Single Cause Single Cure could be interpreted as encouraging patients to seek a single cure. That is not the case. Research has clearly shown that combinations of metabolic acting therapies are synergistic, and have outcomes that far exceed any single agent. We have granted research awarded to investigate synergist "cocktails" of metabolic therapies. The preclinical work is very encouraging. Our goal is to empower patients with these largely non-toxic therapies that may greatly enhance standard of care.
This important publication documents the full remission of a patient with stage 4, triple negative breast cancer. The protocol was designed and refined at Chemothermia Oncology Center in Istanbul Turkey. Dr. Slocum and his colleagues were inspired by the research of Dr. Seyfried and others, and are pioneers in the implementation of metabolic therapies.
Your donations will be directed to keeping doctors from every having to say those words, and if they do, the next words they say will be, “but it’s going to be all right”.
We will allocate funds swiftly, with a singular purpose – to cure cancer.
The unique quality of metabolic therapies is their broad efficacy. While a given drug that targets mutations only has the potential to work on a fraction of the people with a specific type of cancer – drugs that target metabolism work on everyone with cancer, regardless of tissue of origin.
Even though this therapeutic approach has shown incredible preclinical promise, procuring funding is still difficult. The vast majority of funding continues to be allocated to research focusing on single mutations, or narrow pathways that have proven, time and time again, to be largely irrelevant to the course of the disease.
Our focused approach is unique among foundations, allowing for collaborative synergy. Not only do we directly fund research, but we will sponsor symposiums aware that innovation is born out of a collective effort.
Other foundations typically focus on one single cancer type; we focus on the one feature of cancer that pervades all cancer types – defective metabolism.
Sadly, because metabolic therapies like the ketogenic diet, hyperbaric oxygen, and re-purposed drugs are unable to be patented they sit on the side-lines.
Our goal is to fund the research that may demonstrate the efficacy of these therapies so they may be incorporated in to the oncology clinic--for everyone.